Review
doi: 10.2174/157488710790820490.
The pulse of drug development for Alzheimer's disease
Affiliations
- PMID: 20205688
- DOI: 10.2174/157488710790820490
Item in Clipboard
Review
The pulse of drug development for Alzheimer's disease
Rev Recent Clin Trials.
2010 Jan.
Abstract
Therapies that are believed to target the underlying mechanisms of Alzheimer's disease have now reached human clinical trials, with the number of agents in late stage development having increased dramatically in recent years. Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimer's disease, and tau protein which, when hyperphosphorylated, results in the formation of neurofibrillary tangles of paired helical filaments, also believed to be involved in the pathogenesis of Alzheimer's disease. In this review, the current status of Alzheimer's Disease therapies under study is discussed, including the scientific basis for each strategy.
Similar articles
-
Status and future directions of clinical trials in Alzheimer's disease.Int Rev Neurobiol. 2020;154:3-50. doi: 10.1016/bs.irn.2020.03.022. Epub 2020 Jul 20. Int Rev Neurobiol. 2020. PMID: 32739008 Review.
-
Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.Aging Clin Exp Res. 2009 Dec;21(6):386-406. doi: 10.1007/BF03327445. Aging Clin Exp Res. 2009. PMID: 20154508 Review.
-
[Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].Nervenarzt. 2010 Nov;81(11):1289-90, 1292, 1294, passim. doi: 10.1007/s00115-010-3052-2. Nervenarzt. 2010. PMID: 20842339 German.
-
Recent developments in Alzheimer's disease therapeutics.BMC Med. 2009 Feb 19;7:7. doi: 10.1186/1741-7015-7-7. BMC Med. 2009. PMID: 19228370 Free PMC article. Review.
-
[Therapy of Alzheimer disease].Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Neuropsychopharmacol Hung. 2009. PMID: 19731816 Review. Hungarian.
Cited by
-
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.EC Pharmacol Toxicol. 2019 Jul;7(7):547-558. Epub 2019 Jun 21. EC Pharmacol Toxicol. 2019. PMID: 31565701 Free PMC article.
-
The general public's willingness to pay for tax increases to support unrestricted access to an Alzheimer's disease medication.Pharmacoeconomics. 2012 Nov 1;30(11):1085-95. doi: 10.2165/11594180-000000000-00000. Pharmacoeconomics. 2012. PMID: 22938161
-
Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures.J Alzheimers Dis. 2022;87(1):83-100. doi: 10.3233/JAD-215699. J Alzheimers Dis. 2022. PMID: 35342092 Free PMC article. Review.
-
An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.PLoS One. 2016 Mar 29;11(3):e0152471. doi: 10.1371/journal.pone.0152471. eCollection 2016. PLoS One. 2016. PMID: 27023444 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
